Somasekar Seshagiri from 1012 Porto Marino Way, San Carlos, CA 94070, Phone: 6508029897

Ce) And Chief Strategy Officer

view source

Location:

1012 Porto Marino Dr, San Carlos, CA 94070

Industry:

Biotechnology

Work:

Genentech
Associate Director and Staff Scientist
Genentech
Associate Director and Principal Scientist
Antlera Therapeutics
Ce) and Chief Strategy Officer

Vehicle Records

Somasekar Seshagiri
view source
Address:

1012 Porto Marino Dr, San Carlos, CA 94070
Phone:

6508029897
VIN:

WDDGF5EB6BR137114
Make:

MERCEDES-BENZ
Model:

C-CLASS
Year:

2011

Us Patents

Pro34128 Antibodies
view source
US Patent:

7576185, Aug 18, 2009
Filed:

Feb 20, 2007
Appl. No.:

11/709185
Inventors:

J. Christopher Grimaldi - San Francisco CA, US
Somasekar Seshagiri - San Carlos CA, US
Jeremy Stinson - San Mateo CA, US
William I. Wood - Cupertino CA, US
Zemin Zhang - Foster City CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C07K 16/18
A61K 39/395
US Classification:

5303871, 5303881, 5303873, 4241301
Abstract:

The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Pro34128 Polypeptides
view source
US Patent:

7642242, Jan 5, 2010
Filed:

Feb 20, 2007
Appl. No.:

11/708911
Inventors:

J. Christopher Grimaldi - San Francisco CA, US
Somasekar Seshagiri - San Carlos CA, US
Jeremy Stinson - San Mateo CA, US
William I. Wood - Cupertino CA, US
Zemin Zhang - Foster City CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 38/17
C07K 14/435
US Classification:

514 12, 530350
Abstract:

The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Egfr Mutations
view source
US Patent:

7932026, Apr 26, 2011
Filed:

Jun 2, 2005
Appl. No.:

11/145566
Inventors:

Somasekar Seshagiri - San Carlos CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12Q 1/68
C12P 19/34
C12M 1/34
G01N 33/48
US Classification:

435 6, 435 912, 4352871, 436 63, 436 64
Abstract:

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Egfr Mutations
view source
US Patent:

7960118, Jun 14, 2011
Filed:

Nov 17, 2008
Appl. No.:

12/272321
Inventors:

Somasekar Seshagiri - San Carlos CA, US
Assignee:

Genentech, Inc. - San Francisco CA
International Classification:

C12Q 1/68
US Classification:

435 6
Abstract:

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Egfr Mutations
view source
US Patent:

8232053, Jul 31, 2012
Filed:

Apr 27, 2011
Appl. No.:

13/095342
Inventors:

Somasekar Seshagiri - San Carlos CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/53
US Classification:

435 61, 435 72
Abstract:

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Egfr Mutations
view source
US Patent:

8232062, Jul 31, 2012
Filed:

Apr 27, 2011
Appl. No.:

13/095362
Inventors:

Somasekar Seshagiri - San Carlos CA, US
Assignee:

Genetech, Inc. - South San Francisco CA
International Classification:

G01N 33/53
US Classification:

435 72
Abstract:

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Method Of Treating Colorectal Cancer Tumor
view source
US Patent:

8535670, Sep 17, 2013
Filed:

Jun 29, 2012
Appl. No.:

13/537739
Inventors:

Somasekar Seshagiri - San Carlos CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 39/395
US Classification:

4241381, 4241431, 435 723
Abstract:

The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Novel Polypeptides Having Sequence Similarity To Gdnfr And Nucleic Acids Encoding The Same
view source
US Patent:

20040002088, Jan 1, 2004
Filed:

Feb 18, 2003
Appl. No.:

10/369904
Inventors:

J. Grimaldi - San Francisco CA, US
Somasekar Seshagiri - San Carlos CA, US
Jeremy Stinson - San Mateo CA, US
William Wood - Hillsborough CA, US
Zemin Zhang - Foster City CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12Q001/68
C07H021/04
C12P021/02
C12N005/06
C07K014/705
C07K016/28
US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 530/388220, 536/023500
Abstract:

The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.